Accessibility Menu
Arrow-Thin-Down
S&P 500
6,857.12
+0.1%
+7.40
Arrow-Thin-Down
DJI
47,850.94
-0.1%
-31.96
Arrow-Thin-Down
NASDAQ
23,505.14
+0.2%
+51.04
Arrow-Thin-Down
Bitcoin
$92,460.00
-0.7%
-$679.80
Arrow-Thin-Down
AAPL
$280.16
-1.4%
-$3.99
Arrow-Thin-Down
AMZN
$228.97
-1.5%
-$3.41
Arrow-Thin-Down
GOOG
$318.39
-0.7%
-$2.23
Arrow-Thin-Down
META
$661.53
+3.4%
+$21.93
Arrow-Thin-Down
MSFT
$480.37
+0.6%
+$2.64
Arrow-Thin-Down
NVDA
$183.38
+2.1%
+$3.80
Arrow-Thin-Down
TSLA
$454.53
+1.7%
+$7.79
Daily Stock GainersDaily Stock LosersMost Active Stocks
Silexion Therapeutics Stock Quote

Silexion Therapeutics (NASDAQ: SLXN)

$3.17
(15.2%)
+0.42
Price as of December 4, 2025, 3:59 p.m. ET

KEY DATA POINTS

Current Price
$3.17
Daily Change
(15.2%) +$0.42
Day's Range
$2.67 - $3.24
Previous Close
$3.17
Open
$2.75
Beta
0.50
Volume
118,340
Average Volume
485,556
Sector
Health Care
Market Cap
9.9M
Market Cap / Employee
$3.17M
52wk Range
$2.13 - $63.45
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$25.21
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Silexion Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
SLXN-92.49%N/AN/A-100%
S&P+13.22%+85.17%+13.11%+68%
Advertisement

Silexion Therapeutics Company Info

Silexion Therapeutics Corp. engages in the discovery and development of treatments for KRAS-driven cancers. The company is headquartered in Modiin, Israel.

News & Analysis

No results found

No news articles found for Silexion Therapeutics.

Financial Health

General

Q3 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.00M81.8%
Market Cap$7.22M23.0%
Market Cap / Employee$0.52M0.0%
Employees140.0%
Net Income-$3.26M72.5%
EBITDA-$3.29M59.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$9.27M358.2%
Inventory00.0%

Liabilities

Q3 2025YOY Change
Long Term Debt$1.85M-54.7%
Short Term Debt$0.17M-24.0%

Ratios

Q3 2025YOY Change
Return On Assets-125.80%158.7%
Return On Invested Capital795.84%764.8%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$2.84M44.5%
Operating Free Cash Flow-$2.84M44.3%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Book-0.933.7058.6816.42-1380.54%
Price to Tangible Book Value-8.18-7.6540.8416.42-84.81%
Price to Free Cash Flow TTM137.36-
Enterprise Value to EBITDA-3.65-2.89-3.181.03-254.58%
Free Cash Flow Yield0.7%-
Return on Equity-3.8%-590.4%-1342.6%-771.2%42569.68%
Total Debt$4.49M$3.48M$3.70M$2.03M-53.04%

No results found

No podcast episodes available.

No results found

No transcripts available.

Advertisement

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services